Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Nanexa

3.89 SEK

+1.04 %

Less than 1K followers

NANEXA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+1.04 %
+7.02 %
-12.70 %
+132.63 %
+75.00 %
+183.58 %
+3.74 %
-61.54 %
-52.51 %

Nanexa is a drug delivery company with a proprietary platform used for the formulation of injectable depot drugs that create a supply of drugs to the blood. The company's technology is based on encapsulating drug particles with a thin shell and creating opportunities for pharmaceutical companies to develop new products. Nanexa has collaborations with several pharmaceutical companies, mainly around the Nordic market.

Read more
Market cap
654.95M SEK
Turnover
1.07M SEK
Revenue
36.15M
EBIT %
-24.26 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
29/4
2026

Interim report Q1'26

12/5
2026

General meeting '26

27/8
2026

Interim report Q2'26

All
Webcasts
Press releases
3rd party
ShowingAll content types
Third party research2/20/2026, 7:41 AM

Nanexa: Funding secured as semaglutide pivot sharpens commercial focus - Emergers

Following the breakthrough license deal with Moderna, a global leader in mRNA therapeutics, in Q4’25, Nanexa now pursues two main tracks to leverage its PharmaShell technology into commercial value creation: the Moderna license development agreement ...

Nanexa
Regulatory press release2/19/2026, 7:01 AM

Nanexa publicerar bokslutskommuniké och Q4-rapport 2025

Nanexa
Regulatory press release2/19/2026, 7:01 AM

Nanexa publishes year-end report and Q4 report 2025

Nanexa

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release1/27/2026, 7:30 AM

Nanexa presenterar banbrytande prekliniska data som visar en exceptionell farmakokinetisk profil för månadsdosering av semaglutid

Nanexa
Regulatory press release1/27/2026, 7:30 AM

Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation

Nanexa
Press release12/12/2025, 8:37 AM

Investor Studios: Nanexas VD David Westberg gästar Market Update live 11.00

Nanexa
Third party research12/12/2025, 7:12 AM

Nanexa: First license with Moderna an important validation of PharmaShell - Emergers

The announcement of Nanexa’s first licensing deal marks a meaningful validation of the PharmaShell platform, as Moderna, a global leader in mRNA therapeutics, commits to test up to five compounds under a structure including USD 3m upfront, up to USD ...

Nanexa
Press release12/12/2025, 7:00 AM

Emergers: Equity Research | NANEXA: First license with Moderna an important validation of PharmaShell

Nanexa
Regulatory press release12/10/2025, 9:35 PM

Nanexa och Moderna ingår licens- och optionsavtal för utveckling av produkter baserade på PharmaShell®

Nanexa
Regulatory press release12/10/2025, 9:35 PM

Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products

Nanexa
Third party research11/7/2025, 8:58 AM

Nanexa: Intensified focus on deals amid growing funding pressure - Emergers

Nanexa’s Q3 report underscores a pivotal moment for the company. While interest in its PharmaShell technology remains strong, with advanced business discussions ongoing and an extended evaluation agreement in a multi-billion-dollar indication, the financial...

Nanexa
Press release11/7/2025, 7:00 AM

Emergers: Equity Research | NANEXA: Intensified focus on deals amid growing funding pressure

Nanexa
Regulatory press release11/6/2025, 7:00 AM

Nanexa publicerar delårsrapport för januari-september 2025

Nanexa
Regulatory press release11/6/2025, 7:00 AM

Nanexa publishes interim report for January-September 2025

Nanexa
Press release10/16/2025, 6:25 AM

Nanexa utvalt som finalist i Fierce Innovation Awards Life Sciences Edition 2025

Nanexa
Press release10/16/2025, 6:25 AM

Nanexa named as finalist in Fierce Innovation Awards Life Sciences Edition 2025

Nanexa
Regulatory press release10/1/2025, 10:40 AM

Nanexa AB byter Certified Adviser till Tapper Partners AB

Nanexa
Regulatory press release10/1/2025, 10:40 AM

Nanexa AB changes Certified Adviser to Tapper Partners AB

Nanexa
Press release9/22/2025, 6:00 AM

Nanexa erhåller japanskt patentgodkännande för specifik PharmaShell-struktur

Nanexa
Press release9/22/2025, 6:00 AM

Nanexa receives Japanese patent approval for specific PharmaShell structure

Nanexa
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.